MDA-MB-435S - Cell Line (ID:50030)

HMS LINCS ID: 50030
Name: MDA-MB-435S
Alternative Names:
LINCS ID: LCL-1307
Alternative ID: CLO_0007638
Parent Cell Line:
Reference Source: ATCC HTB-129
Organism: Homo sapiens
Organ: skin
Tissue:
Cell Type: melanocyte
Details of Cell Type:
Donor Sex: female
Donor Age:
Donor Ethnicity:
Donor Health Status:
Disease: DOID:1909, malignant melanoma (updated based on http://www.atcc.org/products/all/HTB-129.aspx)
Details of Disease:
Production Details:
Genetic Modification(s): none
Known Mutations:
Citation Information for Mutations:
Verification Reference Profile: DNA Profile (STR, source: ATCC): Amelogenin: X CSF1PO: 11 D13S317: 12 D16S539: 13 D5S818: 12 D7S820: 8,10 THO1: 6,7 TPOX: 8,11 vWA: 16,18
Growth Properties: adherent
Recommended Culture Conditions: From MGH/CMT as specified by cell provider: Leibovitz's L-15 medium with 2 mM L-glutamine supplemented with 0.01 mg/ml insulin, 90%; fetal bovine serum, 10%. Protocol: Remove medium, add fresh 0.25%trypsin - 0.053 mM EDTA, rinse and remove. Place flask at room temperature (or incubated at 37C) for approximately 10 minutes or until the cells detach. Add fresh medium, aspirate and dispense into new flasks. Subcultivation ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Relevant Citations:
Usage Note:
Comments:
Date Publicly Available: 2012-04-25
Most Recent Update: 2016-07-12

Batch Information for HMSL50030-1:

HMS LINCS Batch ID: 50030-1
Provider: Center for Molecular Therapeutics (CMT; Massachusetts General Hospital)
Provider Catalog ID: MGH-419
Provider Batch ID:
Source Information: Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).
Date Received:
HMS QC Outcome:
Transient Modification(s):
Comments:
Date Publicly Available: 2012-04-25
Most Recent Update: 2015-06-29